Receptor activator NF-κB ligand (RANKL) expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathy, osteoarthritis, and from normal patients: semiquantitative and quantitative analysis
Objectives: To compare receptor activator of NF-κB ligand (RANKL) production in the synovial tissue from patients with active rheumatoid arthritis (RA), inactive RA, spondyloarthropathies (SpA), osteoarthritis, and from normal subjects. In addition, to establish the cell lineages expressing RANKL in...
Gespeichert in:
Veröffentlicht in: | Annals of the rheumatic diseases 2002-12, Vol.61 (12), p.1047-1054 |
---|---|
Hauptverfasser: | , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 1054 |
---|---|
container_issue | 12 |
container_start_page | 1047 |
container_title | Annals of the rheumatic diseases |
container_volume | 61 |
creator | Crotti, T N Smith, M D Weedon, H Ahern, M J Findlay, D M Kraan, M Tak, P P Haynes, D R |
description | Objectives: To compare receptor activator of NF-κB ligand (RANKL) production in the synovial tissue from patients with active rheumatoid arthritis (RA), inactive RA, spondyloarthropathies (SpA), osteoarthritis, and from normal subjects. In addition, to establish the cell lineages expressing RANKL in these tissues. Methods: Immunohistological analysis of frozen synovial tissue biopsy specimens was performed using a monoclonal antibody (mAb) to detect RANKL. Sections were evaluated by computer assisted image analysis and semiquantitative analysis to compare RANKL expression between groups. Dual and sequential labelling with mAb RANKL and cell lineage specific monoclonal antibodies were used to determine the types of cells expressing RANKL. Results: Higher levels of RANKL were expressed in tissues from patients with active RA and SpA than in tissues from patients with inactive RA, osteoarthritis, and from normal subjects. RANKL protein was associated with CD3 antigen-positive lymphocytes and some macrophages. RANKL was predominantly associated with activated, memory T cells (CD45Ro positive cells) in patients with active RA and spondyloarthropathy (SpA). Conclusions: The highest levels of RANKL were detected in patients with RA with active synovitis and in some patients with SpA. An increase in RANKL in the inflamed joint of patients with RA, produced by infiltrating activated T cells and macrophages, is likely to be an important cause of joint erosions in RA. |
doi_str_mv | 10.1136/ard.61.12.1047 |
format | Article |
fullrecord | <record><control><sourceid>istex_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_1753975</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>ark_67375_NVC_P3CT554J_3</sourcerecordid><originalsourceid>FETCH-LOGICAL-b310t-d1bbbcf6bafcde2145ab9c85141ed3d6f114e6d1994ddd6c139fc8a4cc872f0b3</originalsourceid><addsrcrecordid>eNpdks2O0zAQgC0EYkvhytkXJFbaFE_sOAkHpKVi-asKWi1cLcd2tl6SONhu2b4aD8Gdt8Ftl-XnYNme-eYbyxqEHgOZAVD-THo94zCDfAaElXfQBBivspxwchdNCCE0YzUvj9CDEK7SlVRQ3UdHkLO8LiidoJ_nRpkxOo-linYjd6flWfbj-0vc2Us5aPz0_HT5fnGMzfXoTQjWDdgOOGwHt7Gyw9GGsDa49a7Ho4zWDDHgbzausF-ZdZ-EVmPp48rbhJ7gMLpBbzu3D7lUsdqeYBeicX9Bu7574-B8n5r8Fj_HwfT261oO0cYU25g9-l9Adttgw0N0r5VdMI9u9in6dPbqYv4mW3x4_XZ-usgaCiRmGpqmUS1vZKu0yYEVsqlVVQADo6nmLQAzXENdM601V0DrVlWSKVWVeUsaOkUvDt5x3fRGq_ROLzsxettLvxVOWvFvZrArcek2AsqC1mlN0ZMbgQxKdq2Xg7LhVgCMkDqHPHHZgbPpt65v89J_EbykZSGWn-fiI51fFAV7J2jijw9801_9sRGxm5tUpQUHAbnYzQ39Befgvcs</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Receptor activator NF-κB ligand (RANKL) expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathy, osteoarthritis, and from normal patients: semiquantitative and quantitative analysis</title><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Crotti, T N ; Smith, M D ; Weedon, H ; Ahern, M J ; Findlay, D M ; Kraan, M ; Tak, P P ; Haynes, D R</creator><creatorcontrib>Crotti, T N ; Smith, M D ; Weedon, H ; Ahern, M J ; Findlay, D M ; Kraan, M ; Tak, P P ; Haynes, D R</creatorcontrib><description>Objectives: To compare receptor activator of NF-κB ligand (RANKL) production in the synovial tissue from patients with active rheumatoid arthritis (RA), inactive RA, spondyloarthropathies (SpA), osteoarthritis, and from normal subjects. In addition, to establish the cell lineages expressing RANKL in these tissues. Methods: Immunohistological analysis of frozen synovial tissue biopsy specimens was performed using a monoclonal antibody (mAb) to detect RANKL. Sections were evaluated by computer assisted image analysis and semiquantitative analysis to compare RANKL expression between groups. Dual and sequential labelling with mAb RANKL and cell lineage specific monoclonal antibodies were used to determine the types of cells expressing RANKL. Results: Higher levels of RANKL were expressed in tissues from patients with active RA and SpA than in tissues from patients with inactive RA, osteoarthritis, and from normal subjects. RANKL protein was associated with CD3 antigen-positive lymphocytes and some macrophages. RANKL was predominantly associated with activated, memory T cells (CD45Ro positive cells) in patients with active RA and spondyloarthropathy (SpA). Conclusions: The highest levels of RANKL were detected in patients with RA with active synovitis and in some patients with SpA. An increase in RANKL in the inflamed joint of patients with RA, produced by infiltrating activated T cells and macrophages, is likely to be an important cause of joint erosions in RA.</description><identifier>ISSN: 0003-4967</identifier><identifier>EISSN: 1468-2060</identifier><identifier>DOI: 10.1136/ard.61.12.1047</identifier><identifier>PMID: 12429533</identifier><identifier>CODEN: ARDIAO</identifier><language>eng</language><publisher>London: BMJ Publishing Group Ltd and European League Against Rheumatism</publisher><subject>3-amino-9-ethylcarbazole ; AEC ; Biological and medical sciences ; bone ; DIA ; digital image analysis ; Diseases of the osteoarticular system ; Extended Report ; fibroblast-like synoviocytes ; FLS ; horseradish peroxidase ; HRP ; immunohistochemistry ; Inflammatory joint diseases ; integrated optical density ; interleukin ; IOD ; mAb ; mean optical density ; Medical sciences ; MOD ; monoclonal antibody ; OPG ; Osteoarthritis ; osteoprotegerin ; RANK ; RANKL ; receptor activator NF-κB ligand ; receptor activator of NF-κB ; receptor activator of NF-κB ligand ; rheumatoid arthritis ; semiquantitative assessment ; SpA ; spondyloarthropathies ; spondyloarthropathy ; SQA ; TNF ; tumour necrosis factor</subject><ispartof>Annals of the rheumatic diseases, 2002-12, Vol.61 (12), p.1047-1054</ispartof><rights>Copyright 2002 by Annals of the Rheumatic Diseases</rights><rights>2003 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC1753975/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC1753975/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,315,728,781,785,886,27928,27929,53795,53797</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=14009212$$DView record in Pascal Francis$$Hfree_for_read</backlink></links><search><creatorcontrib>Crotti, T N</creatorcontrib><creatorcontrib>Smith, M D</creatorcontrib><creatorcontrib>Weedon, H</creatorcontrib><creatorcontrib>Ahern, M J</creatorcontrib><creatorcontrib>Findlay, D M</creatorcontrib><creatorcontrib>Kraan, M</creatorcontrib><creatorcontrib>Tak, P P</creatorcontrib><creatorcontrib>Haynes, D R</creatorcontrib><title>Receptor activator NF-κB ligand (RANKL) expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathy, osteoarthritis, and from normal patients: semiquantitative and quantitative analysis</title><title>Annals of the rheumatic diseases</title><addtitle>Ann Rheum Dis</addtitle><description>Objectives: To compare receptor activator of NF-κB ligand (RANKL) production in the synovial tissue from patients with active rheumatoid arthritis (RA), inactive RA, spondyloarthropathies (SpA), osteoarthritis, and from normal subjects. In addition, to establish the cell lineages expressing RANKL in these tissues. Methods: Immunohistological analysis of frozen synovial tissue biopsy specimens was performed using a monoclonal antibody (mAb) to detect RANKL. Sections were evaluated by computer assisted image analysis and semiquantitative analysis to compare RANKL expression between groups. Dual and sequential labelling with mAb RANKL and cell lineage specific monoclonal antibodies were used to determine the types of cells expressing RANKL. Results: Higher levels of RANKL were expressed in tissues from patients with active RA and SpA than in tissues from patients with inactive RA, osteoarthritis, and from normal subjects. RANKL protein was associated with CD3 antigen-positive lymphocytes and some macrophages. RANKL was predominantly associated with activated, memory T cells (CD45Ro positive cells) in patients with active RA and spondyloarthropathy (SpA). Conclusions: The highest levels of RANKL were detected in patients with RA with active synovitis and in some patients with SpA. An increase in RANKL in the inflamed joint of patients with RA, produced by infiltrating activated T cells and macrophages, is likely to be an important cause of joint erosions in RA.</description><subject>3-amino-9-ethylcarbazole</subject><subject>AEC</subject><subject>Biological and medical sciences</subject><subject>bone</subject><subject>DIA</subject><subject>digital image analysis</subject><subject>Diseases of the osteoarticular system</subject><subject>Extended Report</subject><subject>fibroblast-like synoviocytes</subject><subject>FLS</subject><subject>horseradish peroxidase</subject><subject>HRP</subject><subject>immunohistochemistry</subject><subject>Inflammatory joint diseases</subject><subject>integrated optical density</subject><subject>interleukin</subject><subject>IOD</subject><subject>mAb</subject><subject>mean optical density</subject><subject>Medical sciences</subject><subject>MOD</subject><subject>monoclonal antibody</subject><subject>OPG</subject><subject>Osteoarthritis</subject><subject>osteoprotegerin</subject><subject>RANK</subject><subject>RANKL</subject><subject>receptor activator NF-κB ligand</subject><subject>receptor activator of NF-κB</subject><subject>receptor activator of NF-κB ligand</subject><subject>rheumatoid arthritis</subject><subject>semiquantitative assessment</subject><subject>SpA</subject><subject>spondyloarthropathies</subject><subject>spondyloarthropathy</subject><subject>SQA</subject><subject>TNF</subject><subject>tumour necrosis factor</subject><issn>0003-4967</issn><issn>1468-2060</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2002</creationdate><recordtype>article</recordtype><recordid>eNpdks2O0zAQgC0EYkvhytkXJFbaFE_sOAkHpKVi-asKWi1cLcd2tl6SONhu2b4aD8Gdt8Ftl-XnYNme-eYbyxqEHgOZAVD-THo94zCDfAaElXfQBBivspxwchdNCCE0YzUvj9CDEK7SlVRQ3UdHkLO8LiidoJ_nRpkxOo-linYjd6flWfbj-0vc2Us5aPz0_HT5fnGMzfXoTQjWDdgOOGwHt7Gyw9GGsDa49a7Ho4zWDDHgbzausF-ZdZ-EVmPp48rbhJ7gMLpBbzu3D7lUsdqeYBeicX9Bu7574-B8n5r8Fj_HwfT261oO0cYU25g9-l9Adttgw0N0r5VdMI9u9in6dPbqYv4mW3x4_XZ-usgaCiRmGpqmUS1vZKu0yYEVsqlVVQADo6nmLQAzXENdM601V0DrVlWSKVWVeUsaOkUvDt5x3fRGq_ROLzsxettLvxVOWvFvZrArcek2AsqC1mlN0ZMbgQxKdq2Xg7LhVgCMkDqHPHHZgbPpt65v89J_EbykZSGWn-fiI51fFAV7J2jijw9801_9sRGxm5tUpQUHAbnYzQ39Befgvcs</recordid><startdate>20021201</startdate><enddate>20021201</enddate><creator>Crotti, T N</creator><creator>Smith, M D</creator><creator>Weedon, H</creator><creator>Ahern, M J</creator><creator>Findlay, D M</creator><creator>Kraan, M</creator><creator>Tak, P P</creator><creator>Haynes, D R</creator><general>BMJ Publishing Group Ltd and European League Against Rheumatism</general><general>BMJ</general><scope>BSCLL</scope><scope>IQODW</scope><scope>5PM</scope></search><sort><creationdate>20021201</creationdate><title>Receptor activator NF-κB ligand (RANKL) expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathy, osteoarthritis, and from normal patients: semiquantitative and quantitative analysis</title><author>Crotti, T N ; Smith, M D ; Weedon, H ; Ahern, M J ; Findlay, D M ; Kraan, M ; Tak, P P ; Haynes, D R</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b310t-d1bbbcf6bafcde2145ab9c85141ed3d6f114e6d1994ddd6c139fc8a4cc872f0b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2002</creationdate><topic>3-amino-9-ethylcarbazole</topic><topic>AEC</topic><topic>Biological and medical sciences</topic><topic>bone</topic><topic>DIA</topic><topic>digital image analysis</topic><topic>Diseases of the osteoarticular system</topic><topic>Extended Report</topic><topic>fibroblast-like synoviocytes</topic><topic>FLS</topic><topic>horseradish peroxidase</topic><topic>HRP</topic><topic>immunohistochemistry</topic><topic>Inflammatory joint diseases</topic><topic>integrated optical density</topic><topic>interleukin</topic><topic>IOD</topic><topic>mAb</topic><topic>mean optical density</topic><topic>Medical sciences</topic><topic>MOD</topic><topic>monoclonal antibody</topic><topic>OPG</topic><topic>Osteoarthritis</topic><topic>osteoprotegerin</topic><topic>RANK</topic><topic>RANKL</topic><topic>receptor activator NF-κB ligand</topic><topic>receptor activator of NF-κB</topic><topic>receptor activator of NF-κB ligand</topic><topic>rheumatoid arthritis</topic><topic>semiquantitative assessment</topic><topic>SpA</topic><topic>spondyloarthropathies</topic><topic>spondyloarthropathy</topic><topic>SQA</topic><topic>TNF</topic><topic>tumour necrosis factor</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Crotti, T N</creatorcontrib><creatorcontrib>Smith, M D</creatorcontrib><creatorcontrib>Weedon, H</creatorcontrib><creatorcontrib>Ahern, M J</creatorcontrib><creatorcontrib>Findlay, D M</creatorcontrib><creatorcontrib>Kraan, M</creatorcontrib><creatorcontrib>Tak, P P</creatorcontrib><creatorcontrib>Haynes, D R</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Annals of the rheumatic diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Crotti, T N</au><au>Smith, M D</au><au>Weedon, H</au><au>Ahern, M J</au><au>Findlay, D M</au><au>Kraan, M</au><au>Tak, P P</au><au>Haynes, D R</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Receptor activator NF-κB ligand (RANKL) expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathy, osteoarthritis, and from normal patients: semiquantitative and quantitative analysis</atitle><jtitle>Annals of the rheumatic diseases</jtitle><addtitle>Ann Rheum Dis</addtitle><date>2002-12-01</date><risdate>2002</risdate><volume>61</volume><issue>12</issue><spage>1047</spage><epage>1054</epage><pages>1047-1054</pages><issn>0003-4967</issn><eissn>1468-2060</eissn><coden>ARDIAO</coden><abstract>Objectives: To compare receptor activator of NF-κB ligand (RANKL) production in the synovial tissue from patients with active rheumatoid arthritis (RA), inactive RA, spondyloarthropathies (SpA), osteoarthritis, and from normal subjects. In addition, to establish the cell lineages expressing RANKL in these tissues. Methods: Immunohistological analysis of frozen synovial tissue biopsy specimens was performed using a monoclonal antibody (mAb) to detect RANKL. Sections were evaluated by computer assisted image analysis and semiquantitative analysis to compare RANKL expression between groups. Dual and sequential labelling with mAb RANKL and cell lineage specific monoclonal antibodies were used to determine the types of cells expressing RANKL. Results: Higher levels of RANKL were expressed in tissues from patients with active RA and SpA than in tissues from patients with inactive RA, osteoarthritis, and from normal subjects. RANKL protein was associated with CD3 antigen-positive lymphocytes and some macrophages. RANKL was predominantly associated with activated, memory T cells (CD45Ro positive cells) in patients with active RA and spondyloarthropathy (SpA). Conclusions: The highest levels of RANKL were detected in patients with RA with active synovitis and in some patients with SpA. An increase in RANKL in the inflamed joint of patients with RA, produced by infiltrating activated T cells and macrophages, is likely to be an important cause of joint erosions in RA.</abstract><cop>London</cop><pub>BMJ Publishing Group Ltd and European League Against Rheumatism</pub><pmid>12429533</pmid><doi>10.1136/ard.61.12.1047</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0003-4967 |
ispartof | Annals of the rheumatic diseases, 2002-12, Vol.61 (12), p.1047-1054 |
issn | 0003-4967 1468-2060 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_1753975 |
source | EZB-FREE-00999 freely available EZB journals; PubMed Central; Alma/SFX Local Collection |
subjects | 3-amino-9-ethylcarbazole AEC Biological and medical sciences bone DIA digital image analysis Diseases of the osteoarticular system Extended Report fibroblast-like synoviocytes FLS horseradish peroxidase HRP immunohistochemistry Inflammatory joint diseases integrated optical density interleukin IOD mAb mean optical density Medical sciences MOD monoclonal antibody OPG Osteoarthritis osteoprotegerin RANK RANKL receptor activator NF-κB ligand receptor activator of NF-κB receptor activator of NF-κB ligand rheumatoid arthritis semiquantitative assessment SpA spondyloarthropathies spondyloarthropathy SQA TNF tumour necrosis factor |
title | Receptor activator NF-κB ligand (RANKL) expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathy, osteoarthritis, and from normal patients: semiquantitative and quantitative analysis |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-17T09%3A34%3A57IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-istex_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Receptor%20activator%20NF-%CE%BAB%20ligand%20(RANKL)%20expression%20in%20synovial%20tissue%20from%20patients%20with%20rheumatoid%20arthritis,%20spondyloarthropathy,%20osteoarthritis,%20and%20from%20normal%20patients:%20semiquantitative%20and%20quantitative%20analysis&rft.jtitle=Annals%20of%20the%20rheumatic%20diseases&rft.au=Crotti,%20T%20N&rft.date=2002-12-01&rft.volume=61&rft.issue=12&rft.spage=1047&rft.epage=1054&rft.pages=1047-1054&rft.issn=0003-4967&rft.eissn=1468-2060&rft.coden=ARDIAO&rft_id=info:doi/10.1136/ard.61.12.1047&rft_dat=%3Cistex_pubme%3Eark_67375_NVC_P3CT554J_3%3C/istex_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/12429533&rfr_iscdi=true |